MolecuLight^®supports exceptional
Outcomes & Cost Effectiveness

In a groundbreaking RCT, MolecuLight^® imaging dramatically improved DFU healing outcomes. Wound healing rates doubled at 12-weeks (45% vs. 22%), and the presence or absence of bacterial fluorescence reliably predicted the degree of wound closure.

This compelling data highlights how point-of-care bacterial fluorescence imaging can revolutionize the management of diabetic foot ulcers, leading to superior patient outcomes.

MolecuLight^® imaging is fundamentally transforming wound healing and infection control in long-term care, offering a critical leap forward and significantly reducing the burden of complications.

This retrospective real-world study across 55 facilities revealed that patients treated with MolecuLight achieved a 71% higher healing rate, healed 28% faster, were up to 1.8 times more likely to heal, and experienced a dramatic 75% fewer complications.

A “before and after” cohort study showing that fluorescence imaging reduced antibiotic and antimicrobial dressing needs and wound care costs while improving foot ulcer healing rates (39% to 48%).

MolecuLight-guided debridement of deep sternal wound infections significantly reduced healing time, in-hospital infection risk, and antibiotic costs compared to hyperbaric oxygen therapy.

Fluorescence imaging predicted wound area reduction based on bacterial presence, with persistent bacterial loads correlating to worse outcomes. MolecuLight digital wound measurements were significantly more accurate than manual measurements (23% overestimation with ruler).

MolecuLight imaging prevented the need for intravenous antibiotics and hospitalization in 100% of wound-related cellulitis cases by aiding in early diagnosis and bacterial source control.

MolecuLight imaging provided real-time guidance for debridement and antibiotic selection in chronic lower extremity wounds. Removal of bacterial fluorescence signals was associated with
improved wound area reduction.